Key Points {#d30e181}
==========

Direct oral anticoagulants (DOACs) offer an attractive alternative to traditional vitamin K antagonists for reduction in the risk of stroke in patients with nonvalvular atrial fibrillation (AF).The DOACs provided similar or better clinical outcomes compared with vitamin K antagonists in large, randomized, phase 3 trials.There are a number of clinical issues that should be considered when evaluating clinical trials that evaluated DOACs in patients with AF. The difference in each trial design makes a comparison of these agents difficult.

Introduction {#Sec1}
============

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in older adults \[[@CR1], [@CR2]\]. AF is independently associated with an approximate 5-fold increase in a patient's stroke risk \[[@CR3]\], with the risk of stroke attributable to AF increasing with age \[[@CR4]\]. Compared with those without AF, the relative risk (RR) of stroke has been calculated as 4.0-, 2.6-, 3.3-, and 4.5-fold more likely for patients aged 50--59, 60--69, 70--79, and 80--89, respectively \[[@CR5]\]. In addition, the presence of AF at stroke onset is associated with increased mortality and recurrence rates \[[@CR6]\]. Thirty-day and 1-year mortality rates in patients presenting with AF at stroke onset were 32.5 and 49.5 %, respectively, compared with 16.2 and 27.1 % for patients without AF at stroke onset \[[@CR6]\]. Moreover, recurrence rates within the first year of follow-up were higher for patients who presented with AF at the time of stroke onset (6.6 vs. 4.4 %; *p* = 0.046) \[[@CR6]\]. As such, thromboprophylaxis is a common, though often underused \[[@CR7]\], component to the overall management of patients with AF.

Recent guidelines for the management of nonvalvular AF recommend that warfarin or direct-acting oral anticoagulants (DOACs) be used for the prevention of stroke and systemic embolic events (SEE) in patients at risk for such events \[[@CR8], [@CR9]\]. The antithrombotic agent should be selected for the individual patient based on risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The approved DOACs include the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban \[[@CR10]--[@CR13]\]. This review will discuss the study designs, safety, efficacy, and relevance to clinical practice of anticoagulant options for prevention of stroke in patients with nonvalvular AF, including traditional therapy with warfarin and the DOACs dabigatran, rivaroxaban, apixaban, and edoxaban.

Warfarin Therapy {#Sec2}
================

The vitamin K antagonist (VKA) warfarin has been used in clinical practice for many years and has well-established efficacy. Warfarin, dose-adjusted to an international normalized ratio (INR) of 2.0 to 3.0, reduces the risk of stroke in patients with AF by 64 % \[95 % confidence interval (CI) 49--74 %\] compared with placebo/no treatment and by 39 % (95 % CI 22--52 %) compared with antiplatelet therapy \[[@CR14]\]. Despite its long history of use and proven efficacy, warfarin is associated with inherent limitations such as unpredictable pharmacokinetics (PK) and pharmacodynamics (PD) as well as the potential for significant drug--drug and drug--food interactions \[[@CR15]\]. Therefore, patients undergoing warfarin therapy require frequent physician visits for INR monitoring and dose adjustments to maintain a therapeutic level of anticoagulation and reduce the risk of bleeding. In a post hoc analysis of a randomized trial comparing warfarin therapy with antiplatelet therapy in patients with AF, the time in the therapeutic INR range (TTR) varied extensively between the 526 centers analyzed from 15 countries \[[@CR16]\]. For patients on warfarin therapy, at centers below the median TTR of 65 %, there was no decrease in vascular events compared with dual antiplatelet therapy (RR, 0.93; 95 % CI 0.70--1.24, *p* = 0.61) \[[@CR16]\]. However, patients receiving oral anticoagulant therapy at centers with a TTR above 65 % showed a decrease in vascular events (RR, 2.14; 95 % CI 1.61--2.85; *p* \< 0.0001). In a meta-analysis of eight randomized controlled trials in which warfarin was used for stroke prevention in patients with AF, the INR remained in the therapeutic range only 55--68 % of the time \[[@CR17]\]. Major bleeding rates varied across studies and per year, ranging from 1.40 to 3.40 %, but typically decreased with an increased TTR \[[@CR17]\]. Thus, suboptimal INR control can lead to either increased risk of thromboembolic events or increased risk of bleeding.

Bleeding episodes can be a serious and costly consequence associated with warfarin therapy. In an analysis of medical and pharmacy claims from 47,437 patients, 0.4 % of patients had an intracranial hemorrhage, 1.9 % had a major gastrointestinal bleed, and 3.8 % of patients experienced a minor gastrointestinal bleed within 30 days of a warfarin claim \[[@CR18]\]. Mean (standard deviation) unadjusted all-cause healthcare costs were increased in patients with at least one intracranial hemorrhage \[US\$41,903 (US\$56,654)\], or major gastrointestinal bleed \[US\$40,586 (US\$65,164)\] compared with patients with minor gastrointestinal bleed \[US\$24,347 (US\$56,488)\] or no bleeding events \[US\$24,129 (US\$36,425)\] \[[@CR18]\]. Additional costs associated with warfarin therapy can be the result of medication errors that lead to adverse drug reactions \[[@CR19]\]. In the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry, prior bleed (31.1 vs. 16.7, *p* \< 0.0001), high bleeding risk (20.3 vs. 10.3, *p* \< 0.0001), and frequent falls or frailty (20.7 vs. 7.4, *p* \< 0.0001) were more frequently listed as contraindications to receiving anticoagulant therapy in patients with a CHADS~2~ score ≥2 compared with patients with a CHADS~2~ score \<2 \[[@CR20]\], despite the greater risk of stroke attributed to these patients. Thus, there has been interest in developing alternative agents that are easier to manage while providing reduced risk for bleeding and fewer drug and food interactions compared with warfarin therapy.

Direct Oral Anticoagulants Phase 3 Studies {#Sec4}
==========================================

Dabigatran, rivaroxaban, apixaban, and edoxaban have all demonstrated safety and efficacy compared with warfarin in large, randomized clinical trials for the reduction of risk of stroke and SEE in patients with nonvalvular AF \[[@CR21]\]. All patients included in these trials were at an increased risk of stroke due to one or more risk factors, such as previous stroke or transient ischemic attack (TIA), heart failure, diabetes mellitus, hypertension, or age ≥75 years.

Study Design {#Sec5}
------------

The clinical trial designs for the studies are summarized in Table [1](#Tab1){ref-type="table"}. All four trials were noninferiority studies. In RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy with Dabigatran etexilate), patients were randomized to either fixed doses of dabigatran, administered in a blinded fashion, or dose-adjusted warfarin, which was administered open-label \[[@CR22]\]. The other three trials used a double-blind, double-dummy design \[[@CR23]--[@CR25]\]. The ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trials tested a single dose compared with warfarin, while RE-LY and ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trials evaluated two different doses. A twice-daily dosing regimen was used in RE-LY and ARISTOTLE, while ROCKET AF and ENGAGE AF had once-daily dosing. Finally, decreased doses of drug were included in three of the trials. In ARISTOTLE, a decreased dose of apixaban (2.5 mg twice daily) was used in a subset of patients with two or more of the following characteristics: age ≥80 years, body weight ≤60 kg, or a serum creatinine level of ≥1.5 mg/dL \[[@CR23]\]. A reduced dose of rivaroxaban (15 mg once daily) was used in patients with a creatinine clearance (CrCl) of 30--49 mL/min in ROCKET AF \[[@CR23]\]. In ENGAGE AF, patients randomized to either the lower-dose regimen (30 mg edoxaban once daily) or higher-dose regimen (60 mg edoxaban once daily) who had an anticipated increased drug exposure due to a CrCl of 30--50 mL/min, body weight ≤60 kg, or concomitant administration of the strong p-glycoprotein (P-gp) inhibitors verapamil, quinidine, or dronedarone also received a 50 % reduced dose \[[@CR26]\]. In addition, the 50 % dose reduction could occur at any time during the ENGAGE AF trial if any of the above-mentioned three criteria were met \[[@CR26]\].Table 1Comparison of clinical trial design for DOAC clinical trials in patients with atrial fibrillation \[[@CR22]--[@CR25]\]ParameterRE-LY (dabigatran)ROCKET AF (rivaroxaban)ARISTOTLE (apixaban)ENGAGE AF-TIMI 48 (edoxaban)Study designRandomized, dabigatran dosage-blinded, open-label warfarin, parallel-arm, noninferiority studyRandomized, double-blind, double-dummy, event-driven, parallel-arm, noninferiority studyRandomized, double-blind, double-dummy, parallel-arm, noninferiority studyRandomized, double-blind, double-dummy trial, parallel-arm, noninferiority studyPrimary endpoint (analysis population)Stroke or systemic embolism (ITT)Stroke or systemic embolism (PP)Stroke or systemic embolism (ITT)Stroke or systemic embolism (mITT)DosageDabigatran 110 mg or 150 mg BID, or warfarin dose-adjusted to a target INR of 2.0--3.0Rivaroxaban 20 mg once daily or warfarin dose-adjusted to a target INR of 2.0--3.0Apixaban 5 mg BID or warfarin dose-adjusted to a target INR of 2.0--3.0Edoxaban 30 mg or 60 mg once daily, or warfarin dose-adjusted to a target INR of 2.0--3.0Dose reductionNone15 mg once daily for patients with a CrCl of 30--49 mL/min2.5 mg BID in a subset of patients with 2 or more of the following criteria: age ≥80, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL50 % dose reduction was given to patients with CrCl 30--50 mL/min, body weight ≤60 kg, or concomitant use of verapamil, quinidine, or dronedarone at randomization or during studyFollow-up visitsINR measured at least monthly; 14 days after randomization, at 1 and 3 months, every 3 months thereafter in the first year, and then every 4 months until the study ended1, 2, and 4 weeks and monthly thereafterMonthly for INR monitoring; assessment every 3 months; 30 days after last doseINR measured monthly; study visits on days 8, 15, 29, and 60, at month 3, and at least every 3 months thereafter*BID* twice daily, *CrCl* creatinine clearance, *DOAC* direct oral anticoagulant, *INR* international normalized ratio, *ITT* intention to treat population, *mITT* modified intention to treat, *PP* per protocol, as-treated population during treatment

The trials had many similar inclusion criteria, requiring the presence of AF documented by electrocardiography (ECG) (Table [2](#Tab2){ref-type="table"}). However, there are some important differences in the populations enrolled, resulting in differences in risk across trials. The RE-LY and ARISTOTLE trials included patients with a left ventricular ejection fraction of \<40 and ≤40 %, respectively, values that are consistent with a diagnosis of heart failure \[[@CR22], [@CR23]\]. However, ROCKET AF included patients with a left-ventricular ejection fraction of ≤35 %, indicative of a greater risk of cardiac dysfunction \[[@CR24]\]. ROCKET AF and ENGAGE AF recruited patients at higher risk for stroke than RE-LY or ARISTOTLE \[[@CR22]--[@CR25]\]. The presence of AF must have been documented within 30 days before randomization in ROCKET AF, at screening or within 6 months before randomization in RE-LY, and 12 months prior to enrollment in ARISTOTLE and ENGAGE AF \[[@CR22]--[@CR25]\]. Patients with atrial flutter were also included in ARISTOTLE \[[@CR23]\].Table 2Inclusion criteria for clinical trials of DOACs in patients with atrial fibrillation \[[@CR22]--[@CR25]\]ParameterRE-LY (dabigatran)ROCKET AF (rivaroxaban)ARISTOTLE (apixaban)ENGAGE AF-TIMI 48 (edoxaban)Atrial fibrillationNonvalvular AFNonvalvular AFNonvalvular AF or atrial flutter not due to a reversible causeNonvalvular AFDocumented by12‐lead ECG, rhythm strip, pacemaker/ICD ECG, or Holter ECG; the duration of AF should be ≥30 s. ECG (not marker channels or mode switch episodes) from pacemakers and defibrillators can be used to document only 1 episode of paroxysmal or persistent AF12-lead ECG, rhythm strip, Holter, or pacemaker interrogation and have medical evidence of AF before the qualifying ECG evidenceECG, or as an episode lasting at least 1 min on a rhythm strip, Holter recording, or intracardiac ECG (from an implanted pacemaker or defibrillator)12-lead ECG, continuous ECG recording, rhythm strip, intracardiac ECG, pacemaker or implantable cardiac defibrillator interrogationTimeframeOn the day of screening or randomization; or symptomatic episode within 6 months before randomization; or symptomatic or asymptomatic paroxysmal or persistent AF on 2 separate occasions, at least 1 day apart, one of which is within 6 months before randomizationWithin 30 days before randomization and medical evidence within 1 year before and at least 1 day before the ECGOn the day of screening; or on 2 separate occasions at least 2 weeks apart in the 12 months prior to enrollmentWithin the prior 12 monthsStroke risk factorsCHADS~2~ index score ≥1^a^; or age ≥65 years and 1 of the following: diabetes mellitus on treatment; or documented coronary artery disease; or hypertension requiring medical treatmentCHADS~2~ index score ≥2CHADS~2~ index score ≥1CHADS~2~ index score ≥2Age≥18 years≥18 years≥18 years≥21 years*AF* atrial fibrillation, *DOAC* direct oral anticoagulant, *ECG* electrocardiogram, *ICD* implantable cardioverter defibrillator^a^Patients with only diabetes mellitus or hypertension must be ≥65 years of age

Exclusion criteria were generally similar across all trials (Table [3](#Tab3){ref-type="table"}). Patients were ineligible if they had experienced a recent stroke (within 14 days in RE-LY or ROCKET AF; 7 days in ARISTOTLE; 30 days in ENGAGE AF) \[[@CR22]--[@CR25]\]. All trials excluded patients with severe renal dysfunction (CrCl \<30 mL/min), except ARISTOTLE, which excluded patients with CrCl \<25 mL/min or a serum creatinine \>2.5 mg/dL \[[@CR23]\]. Bleeding risk exclusions for recent trauma or major surgery, gastrointestinal bleeding, hemorrhagic disorders, and intracranial bleeding were well defined in RE-LY, ROCKET AF, and ENGAGE AF \[[@CR22], [@CR24], [@CR25]\]. In ARISTOTLE, patients with a bleeding risk believed to be a contraindication to oral anticoagulation were excluded \[[@CR23]\]. Patients were allowed ≤100 mg daily aspirin in the RE-LY, ROCKET AF, and ENGAGE AF trials \[[@CR22], [@CR24], [@CR25]\], and \<165 mg daily aspirin in the ARISTOTLE trial \[[@CR23]\].Table 3Exclusion criteria for clinical trials of DOACs in patients with atrial fibrillation \[[@CR22]-[@CR25]\]ParameterRE-LY (dabigatran)ROCKET AF (rivaroxaban)ARISTOTLE (apixaban)ENGAGE AF-TIMI 48 (edoxaban)**Stroke**Severe, disabling stroke within the previous 6 monthsSevere, disabling stroke within 3 months; TIA within 3 days before the randomization visitIschemic stroke within 7 daysStroke, acute MI, acute coronary syndrome, or percutaneous intervention within the previous 30 daysOr any stroke within 14 days before the randomization visit**Oral anticoagulation**Indication for anticoagulant therapy for a condition other than atrial fibrillation**Contraindications**Contraindication to warfarinContraindication to anticoagulant agents**Life expectancy**\<Expected duration of the trial\<2 years≤1 year\<1 year**Cardiac-related conditions**History of heart valve disorder; transient atrial fibrillation caused by a reversible disorder (e.g., thyrotoxicosis, PE, recent surgery, MI); active endocarditisHistory of heart valve disorder (with the exception of bioprosthetic heart valve or valve repair); transient atrial fibrillation caused by a reversible disorder (e.g., thyrotoxicosis, PE, recent surgery, MI); active endocarditis**Planned AF procedure**Any planned ablation or surgeryPlanned cardioversion (electrical or pharmacological)Any plannedChronic anticoagulation therapy will be discontinued if a planned pharmacologic, electrical, or surgical therapy were to be successful in converting and maintaining normal sinus rhythm**Uncontrolled hypertension**Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHgSystolic blood pressure \>180 mmHg or diastolic blood pressure \>100 mmHgSystolic blood pressure \>170 mmHg or diastolic blood pressure \>100 mmHg**Bleeding risk**History of or condition associated with increased bleeding riskBleeding risk that is a contraindication to oral anticoagulationHistory of or condition associated with increased bleeding riskActive internal bleeding**Planned surgery or intervention**Within the next 3 monthsAny plannedAny plannedAny planned**Trauma or major surgery**Within the previous monthWithin 30 days before randomizationNot definedWithin the previous 10 days**Intracranial, intraocular, spinal, or atraumatic intra-articular bleed**Any historyAny historyNot definedAny history**GI bleed**Within the past year; symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 daysWithin 6 months before randomizationNot definedWithin the previous year**Hemorrhagic disorder**Any historyChronicNot definedAny history**Concurrent aspirin excluded**\>100 mg daily\>100 mg daily\>165 mg daily\>100 mg daily**Concurrent antiplatelet/fibrinolytic therapy**Fibrinolytic agents within 48 hours of study entryAspirin in combination with thienopyridines within 5 days before randomization, IV antiplatelet agents within 5 days before randomization, fibrinolytics within 10 days before randomizationSimultaneous treatment with both aspirin and a thienopyridine (e.g., clopidogrel)Aspirin plus thienopyridine, fibrinolytics**Anti-inflammatory agents**N/AAnticipated need for chronic treatment with NSAIDsNSAIDs should be used with cautionChronic nonaspirin NSAID use (\>4 days/week)**Concomitant therapy**N/ACytochrome P450 3A4 inhibitors (ketoconazole or protease inhibitors) or inducers (rifampin/rifampicin) prohibitedCytochrome P450 3A4 inhibitors (ketoconazole or protease inhibitors), other antithrombotic agents, GP IIb/IIIa inhibitorsCyclosporine, potent P-gp inhibitors, nonstudy anticoagulants**Laboratory parameters**Hemoglobin \<10 g/dL Platelet count \<100,000/mm^3^Hemoglobin \<10 g/dL Platelet count \<90,000/mm^3^Hemoglobin \<9 g/dL Platelet count ≤100,000/mm^3^Hemoglobin \<10 g/dL Platelet count \<100,000/mm^3^**Renal function**Estimated CrCl ≤30 mL/minCalculated CrCl \<30 mL/minSCr \>2.5 mg/dL or calculated CrCl \<25 mL/minCalculated CrCl \<30 mL/min**Hepatic function**Active liver disease (hepatitis A, B, or C), ALT, AST, Alk Phos \>2x the ULNKnown significant liver disease or ALT \>3x the ULNALT or AST \>2x ULN or a total bilirubin \>1.5x ULNActive or persistent liver disease, positive hepatitis B or C test, ALT or AST \>2x ULN or total bilirubin ≥1.5x ULN*AF* atrial fibrillation, *Alk Phos* alkaline phosphatase, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *CrCl* creatinine clearance, *DOAC* direct oral anticoagulant, *GI* gastrointestinal, *GP* glycoprotein, *IV* intravenous, *MI* myocardial infarction, *N*/*A* not available, *NSAID* nonsteroidal anti-inflammatory drug, *PE* pulmonary embolism, *SCr* serum creatinine, *TIA* transient ischemic attack, *ULN* upper limit of normal

All four studies assessed the efficacy and safety of the DOACs for stroke prevention in patients with nonvalvular AF, which was defined as AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair \[[@CR8]\]. It should be noted that mild mitral stenosis was not excluded in ENGAGE AF or ARISTOTLE, and subjects with AF and valvular heart diseases such as mitral valve prolapse, mitral valve regurgitation, and aortic valve disease were allowed in ENGAGE AF \[[@CR23], [@CR25]\]. In ROCKET AF, hemodynamically significant mitral valve stenosis was excluded, and hemodynamically significant valvular disease was excluded in RE-LY \[[@CR22], [@CR24]\].

Primary Endpoint Analyses {#Sec6}
-------------------------

In all trials, the primary efficacy endpoint was noninferiority compared with warfarin for stroke or SEE \[[@CR22]--[@CR25]\]. Of note, there were differences in the analysis populations for the primary efficacy endpoint: RE-LY and ARISTOTLE reported noninferiority for their intent-to-treat (ITT) populations, ROCKET AF reported for the per-protocol population, and ENGAGE AF analyzed the modified ITT (mITT) population (Table [1](#Tab1){ref-type="table"}) \[[@CR22]--[@CR25]\]; thus the ROCKET AF and ENGAGE AF trials' primary efficacy endpoint analyses were performed on on-treatment patients. In RE-LY, ARISTOTLE, and ENGAGE AF, major bleeding was the primary safety endpoint \[[@CR22]--[@CR24]\]. All studies used an adapted version of the International Society of Thrombosis and Hemostasis (ISTH) criteria for major bleeding \[[@CR22]--[@CR25]\]. In the ROCKET AF trial, the composite of major and clinically relevant nonmajor (CRNM) bleeding was the primary safety endpoint \[[@CR24]\].

Patient Characteristics {#Sec7}
=======================

In ROCKET AF, more patients in the warfarin group than patients in the rivaroxaban group had a CHADS~2~ score of 6 (2.2 vs. 1.7 %, respectively) and a previous myocardial infarction (MI) (18.0 vs. 16.6 %, respectively) \[[@CR24]\]. Overall, patients in ROCKET AF and ENGAGE AF were at a greater risk of stroke than patients enrolled in other trials, with higher CHADS~2~ scores overall \[[@CR24], [@CR25]\]. Patients enrolled in ROCKET AF and ENGAGE AF trials also included higher percentages of patients with diabetes, hypertension, and congestive heart failure. More than half the patients in ROCKET AF had a history of stroke or TIA, with lower rates in each of the other three trials. The proportion of patients with paroxysmal AF was higher in RE-LY and in ENGAGE AF than in the other trials.Table 4Characteristics and patient demographics of phase 3 clinical trials \[[@CR22]--[@CR25]\]ParameterRE-LY (dabigatran)ROCKET AF (rivaroxaban)ARISTOTLE (apixaban)ENGAGE AF-TIMI 48 (edoxaban)Patients (*n*)18,11314,26418,20121,105Median age (years)71 (mean)737072Male sex (%)64606562Mean weight (kg)8328 kg/m^2^ (BMI)82 (median)NR Low body weight (%)^a^2.1281110Paroxysmal AF (%)33181525Persistent or permanent AF (%)6781^b^8575CHADS~2~ score Mean2.13.52.12.8 0--1 (%)320^c^34-- 2 (%)36133677 (≤3) 3--6 (%)32873023 (4--6)Previous stroke or TIA (%)20551928Heart failure (%)32633557Diabetes mellitus (%)23402536Hypertension (%)79918794Previous VKA use (%)50625759Previous aspirin use (%)40373129Mean TTR (%)64556265Median TTR (%)NR586668Median follow-up (years)2.01.91.82.8*AF* atrial fibrillation, *NR* not reported, *TIA* transient ischemic attack, *TTR* time in therapeutic range, *VKA* vitamin K antagonist^a^For RE-LY, \<50 kg; ROCKET AF, ≤70 kg; ARISTOTLE and ENGAGE AF-TIMI 48, ≤60 kg^b^1 % were newly diagnosed or new onset^c^3 patients had a score of 1

Clinical Trial Results and Approved Dosing Recommendations {#Sec8}
==========================================================

Dabigatran Etexilate {#Sec9}
--------------------

At a dose of 110 mg twice daily, dabigatran demonstrated noninferiority to warfarin for the prevention of stroke and SEE in patients with nonvalvular AF (*p* \< 0.001 for noninferiority; Table [5](#Tab5){ref-type="table"}) \[[@CR22]\]. Dabigatran 150 mg twice daily was associated with lower rates of stroke and systemic embolism than warfarin (*p* \< 0.001 for superiority) and significantly reduced the risk for ischemic stroke (RR, 0.76; 95 % CI 0.60--0.98; *p* = 0.03) \[[@CR21]\]. Both doses of dabigatran significantly reduced the risk for hemorrhagic stroke compared with warfarin (RR, 0.31; 95 % CI 0.17--0.56, *p* \< 0.001 for dabigatran 110 mg; RR, 0.26; 95 % CI 0.14--0.49; *p* \< 0.001 for dabigatran 150 mg). Event rates for dabigatran were updated following publication of the primary data to reflect inclusion of events potentially related to stroke as well as the addition of patients who did not undergo randomization and several deaths that occurred after the end of the study \[[@CR27], [@CR28]\]. The updated event rates, which did not change the primary conclusions of the study, are captured in Table [5](#Tab5){ref-type="table"}.Table 5Efficacy of DOACs compared with warfarin in phase 3 clinical trials for the prevention of stroke or systemic embolism in patients with atrial fibrillation \[[@CR22]--[@CR25], [@CR28]\]Outcome (ER^a^)RE-LYROCKET AFARISTOTLEENGAGE AF-TIMI 48Dabigatran^b^Edoxaban110 mg (*n* = 6015)^c^150 mg (*n* = 6076)Warfarin (*n* = 6022)Rivaroxaban (*n* = 6958)^b^Warfarin (*n* = 7004)Apixaban (*n* = 9088)^b^Warfarin (*n* = 9052)Lower-dose (*n* = 7002)^b^Higher-dose (*n* = 7012)Warfarin (*n* = 7012)**Primary analysis of primary outcome**Stroke or SEE1.541.121.721.72.21.271.601.611.181.50*p* \< 0.001^d^, *p* = 0.27^e^*p* \< 0.001^d^, *p* \< 0.001^e^*p*  \< 0.001^d^*p* \< 0.001^d^, *p* = 0.01^e^*p* = 0.005^d^, *p* = 0.44^e^*p* \< 0.001^d^, *p* = 0.02^e^Analysis populationITTPPITTmITT**Secondary analysis of primary outcome**Stroke or SEENRNRNR2.12.4NRNR2.041.571.80*p* \< 0.001^d^, *p* = 0.12^e^*p* = 0.10^e^*p* = 0.08^e^Analysis populationITTITT**Secondary efficacy outcomes**Stroke1.441.011.571.651.961.191.511.911.491.69*p* = 0.41*p* \< 0.001*p* = 0.092*p* = 0.01*p* = 0.12*p* = 0.11Ischemic Stroke1.340.931.221.341.420.971.051.771.251.25*p* = 0.42*p* = 0.03*p* = 0.581*p* = 0.42*p* \<0.001*p* = 0.97Hemorrhagic Stroke0.120.100.380.260.440.240.470.160.260.47*p* \< 0.001*p* \< 0.001*p* = 0.024*p* \< 0.001*p* \< 0.001*p* \< 0.001SEENRNRNR0.040.190.090.100.150.080.12*p* = 0.003*p* = 0.70*p* = 0.43*p* = 0.19CV mortality2.432.282.691.531.711.802.022.712.743.17*p* = 0.21*p* = 0.04*p* = 0.289NR*p* = 0.008*p* = 0.013Total mortality3.753.644.131.872.213.523.943.803.994.35*p* = 0.13*p* = 0.051*p* = 0.073*p* = 0.047*p* = 0.006*p* = 0.08*CI* confidence interval, *CV* cardiovascular, *ER* event rate, *GI* gastrointestinal, *ITT* intent to treat analysis, *mITT* modified intent to treat, *NR* not reported, *PP* per protocol, *SEE* systemic embolic event^a^Event rate for RE-LY, ARISTOTLE, and ENGAGE AF was %/year; for ROCKET AF, number/100 PY^b^Data for primary efficacy analysis and ischemic stroke reflect updated values from 2014 \[[@CR28]\]^c^ *n* values for primary analysis^d^Noninferiority^e^Superiority

The rate of major bleeding was similar in patients who received warfarin or dabigatran 150 mg twice daily (*p* = 0.31), and lower in patients who received dabigatran 110 mg twice daily (RR 0.80; 95 % CI 0.69--0.93, *p* = 0.003 compared with warfarin; Table [6](#Tab6){ref-type="table"}) \[[@CR22]\]. There was a significantly higher rate of major gastrointestinal bleeding with dabigatran 150 mg than warfarin (RR, 1.50; 95 % CI 1.19--1.89, *p* \< 0.001) \[[@CR22]\]. The rate of intracranial bleeding was significantly reduced in patients receiving dabigatran 150 mg (RR, 0.40; 95 % CI 0.27--0.60, *p* \< 0.001) or dabigatran 110 mg (RR, 0.31; 95 % CI 0.20--0.47, *p* \< 0.001) compared with warfarin \[[@CR22]\]. Annualized rates of other adverse events were similar between groups, except the rate of dyspepsia was increased with dabigatran 110 mg (11.8 %) and 150 mg (11.3 %) compared with warfarin (5.8 %; *p* \< 0.001 for both comparisons) \[[@CR22]\]. Updated major bleeding rates are reflected in Table [6](#Tab6){ref-type="table"} \[[@CR28]\].Table 6Safety of DOACs compared with warfarin in phase 3 clinical trials for the prevention of stroke or systemic embolism in patients with atrial fibrillation \[[@CR22]--[@CR25], [@CR28]\]Outcome (ER^a^)RE-LYROCKET AFARISTOTLEENGAGE AF-TIMI 48Dabigatran^b^WarfarinRivaroxabanWarfarinApixabanWarfarinEdoxabanWarfarin110 mg150 mgLower-doseHigher-doseMajor bleeding2.923.403.613.63.42.133.091.612.753.43*p* = 0.003*p* = 0.41*p* = 0.58*p* \< 0.001*p* \< 0.001*p* \< 0.001Major or CRNM bleedingNRNRNR14.914.54.076.017.9711.1013.02*p* = 0.44*p* \< 0.001*p* \< 0.001*p* \< 0.001Intracranial bleeding0.230.300.740.50.70.330.800.260.390.85*p* \< 0.001*p* \< 0.001*p* = 0.02*p* \< 0.001*p* \< 0.001*p* \< 0.001GI bleeding1.121.511.023.22.20.760.860.821.511.23*p* = 0.43*p* \< 0.001*p* \< 0.001*p* = 0.37*p* \< 0.001*p* = 0.03Any bleeding14.6216.4218.15NRNR18.125.810.6814.1516.40*p* \< 0.001*p* = 0.002*p* \< 0.001*p* \< 0.001*p* \< 0.001*CI* confidence interval, *CRNM* clinically relevant nonmajor, *DOAC* direct oral anticoagulant, *GI* gastrointestinal, *NR* not reportedAll *p* values for superiority^a^Event rate for RE-LY, ARISTOTLE, and ENGAGE AF was %/year; for ROCKET AF, number/100 PY^b^Data for major bleeding reflect updated values from 2014 \[[@CR28]\]

Dabigatran is approved in the USA, Canada, and Europe at an oral dose of 150 mg twice daily for patients with a CrCl of \>30 mL/min for the reduction of the risk of stroke and SEE \[[@CR11], [@CR29], [@CR30]\]. In the USA, patients with a CrCl of 15--30 mL/min should receive an oral dose of 75 mg twice daily, and dabigatran should be avoided in patients with a CrCl \<15 mL/min or on dialysis \[[@CR11]\]. In Canada and Europe, a reduced dose of 110 mg is recommended for patients with a CrCl of 30--50 mL/min \[[@CR29], [@CR30]\]. A reduced dose of 75 mg twice daily may be given to patients with a CrCl between 30 and 50 mL/min receiving dronedarone or ketoconazole. However, dose adjustments are not necessary for administration with other P-gp inhibitors \[[@CR11]\]. Patients with a CrCl \<30 mL/min who are receiving concomitant P-gp inhibitors should not receive dabigatran \[[@CR11]\]. Dabigatran should not be administered with potent P-gp inducers \[[@CR11]\].

Rivaroxaban {#Sec10}
-----------

In ROCKET AF, rivaroxaban demonstrated noninferiority to warfarin for the prevention of stroke or SEE in patients with nonvalvular AF (*p* \< 0.001 for noninferiority; Table [5](#Tab5){ref-type="table"}) \[[@CR24]\]. Rivaroxaban demonstrated superiority in the on-treatment analysis (*p* = 0.015), but not in the ITT analysis (*p* = 0.12), despite the fact that there is only a difference of 28 patients between these two analysis groups (Table [5](#Tab5){ref-type="table"}). Rates of hemorrhagic stroke were significantly reduced in the rivaroxaban group compared with the warfarin group.

Major and CRNM bleeding rates were similar between groups (*p* = 0.44) (Table [6](#Tab6){ref-type="table"}) \[[@CR24]\]. Patients in the rivaroxaban group experienced lower rates of intracranial hemorrhage \[hazard ratio (HR), 0.67; 95 % CI 0.47--0.93; *p* = 0.02\] and fatal bleeding (HR, 0.50; 95 % CI 0.31--0.79; *p* = 0.003) than patients in the warfarin group \[[@CR24]\]. It should be noted that there was more major gastrointestinal bleeding (3.2 vs. 2.2 %; *p* \< 0.001) and a higher need for transfusion (2.6 vs. 2.15 %; *p* = 0.04) with the use of rivaroxaban compared with warfarin \[[@CR24]\]. Rates of other adverse events were similar between groups.

The reduced dose of rivaroxaban (15 mg once daily) or rivaroxaban placebo, for patients with moderate renal insufficiency, was used in 21 % of patients in both groups \[[@CR24]\]. The primary efficacy and safety outcomes were consistent with the outcomes demonstrated with those who received full dose.

In patients with a CrCl \>50 mL/min, rivaroxaban should be administered with the evening meal at a dose of 20 mg once daily \[[@CR12]\]. Patients with a CrCl of 15--50 mL/min should receive a reduced dose of 15 mg once daily at the evening meal \[[@CR12]\]. Rivaroxaban should not be given with combined P-gp and strong cytochrome P450 3A4 (CYP3A4) inhibitors or combined P-gp and strong CYP3A4 inducers \[[@CR12]\].

Apixaban {#Sec11}
--------

Apixaban demonstrated a lower annualized rate of stroke or SEE than warfarin in patients with AF (*p* \< 0.001 for noninferiority; *p* = 0.01 for superiority; Table [5](#Tab5){ref-type="table"}) \[[@CR23]\]. There was a significant reduction in risk for hemorrhagic stroke among patients who received apixaban compared with warfarin.

Major bleeding rates were lower in the apixaban group compared with the warfarin group (HR, 0.69; 95 % CI 0.60--0.80, *p* \< 0.001) (Table [6](#Tab6){ref-type="table"}). Similarly, major or CRNM bleeding occurred less frequently in patients who received apixaban than patients who received warfarin (HR, 0.68; 95 % CI 0.61--0.75, *p* \< 0.001). Rates of other adverse events were similar between groups.

The reduced dose of apixaban 2.5 mg twice daily was administered in 4.7 % of patients in the apixaban group \[[@CR23]\]. The primary efficacy and safety outcomes were not significantly different for patients who received the 2.5 mg twice-daily dose compared with those who received the full dose.

For the reduction of risk of stroke and SEE in nonvalvular AF, patients should receive oral apixaban 5 mg twice daily \[[@CR10]\]. A reduced oral dose of 2.5 mg twice daily should be given to patients in whom at least two of the following are true: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL \[[@CR10]\]. Patients receiving strong dual inhibitors of CYP3A4 and P-gp should be given a reduced dose of 2.5 mg twice daily. However, patients already taking apixaban 2.5 mg twice daily should avoid coadministration of apixaban with strong dual inhibitors of CYP3A4 and P-gp \[[@CR10]\]. Patients taking strong dual inducers of CYP3A4 and P-gp should not receive apixaban \[[@CR10]\].

Edoxaban {#Sec12}
--------

Both the higher- (60 mg) and lower-dose (30 mg) regimens of edoxaban demonstrated noninferiority to warfarin in prevention of stroke or SEE in patients with AF (HR, 0.79; 97.5 % CI 0.63--0.99, *p* \< 0.001 and HR, 1.07; 97.5 % CI 0.87--1.31, *p* = 0.005, respectively; Table [5](#Tab5){ref-type="table"}) \[[@CR25]\]. Furthermore, higher-dose edoxaban demonstrated superiority (*p* = 0.02) to warfarin when the mITT population was analyzed, but this superiority was lost when the ITT population was tested (*p* = 0.08). Treatment with either dose of edoxaban led to significantly reduced risks for hemorrhagic stroke compared with warfarin (HR, 0.54; 95 % CI 0.38--0.77, *p* \< 0.001 and HR, 0.33; 95 % CI 0.22--0.50, *p* \< 0.001 for higher- and lower-dose edoxaban, respectively). While the efficacy and safety evaluation of edoxaban was stratified by varying degrees of renal function for regulatory approval \[[@CR13]\], a published analysis in this population is not yet available.

Annualized rates of major bleeding were decreased in patients who received either the higher- or lower-dose regimens of edoxaban compared with warfarin (HR, 0.80; 95 % CI 0.71--0.91, *p* \< 0.001; HR, 0.47; 95 % CI 0.41--0.45, *p* \< 0.001) for the higher and lower dose, respectively) (Table [6](#Tab6){ref-type="table"}) \[[@CR25]\].

Rates of stroke or SEE in patients who received the 50 % dose reduction were 2.32 % for the higher-dose group (30 mg), 3.14 % for the lower-dose group (15 mg), and 2.68 % for patients with similar characteristics in the warfarin group. The resulting HRs and corresponding 95 % CIs were not significantly different to those for the full dosing groups \[[@CR25]\]. However, the resulting reductions in the risk for major bleeding were significantly greater for patients in the higher- and lower-dose edoxaban regimens who received a 50 % dose reduction compared to those who did not (*p* = 0.02 and *p* \< 0.01 for interaction, respectively). Major bleeding rates for reduced-dose edoxaban patients were 3.05 % for higher-dose group (30 mg) and 1.50 % for lower-dose group (15 mg) versus 4.85 % for warfarin patients with similar characteristics \[[@CR25]\].

For the prevention of stroke and SEE in patients with nonvalvular AF, edoxaban 60 mg once daily is approved in the USA \[[@CR13]\] and Japan \[[@CR31]\], and is approved in other countries, including the European Union \[[@CR32]\]. Edoxaban should not be used in patients with CrCl \> 95 mL/min \[[@CR13]\]. A reduced, once-daily dose of edoxaban 30 mg should be used in patients with CrCl 15--50 mL/min. Edoxaban should not be coadministered with rifampin \[[@CR13]\].

Subpopulations {#Sec13}
==============

Patients with a history of stroke or TIA are at an increased risk of reoccurrence \[[@CR33]\]. The DOAC trials included patients who had a previous stroke or TIA. There were 3623 patients (20 %) in the RE-LY trial that had a previous stroke or TIA. Of these patients, 2.78 % per year in the warfarin group experienced a stroke or SEE, 2.32 % per year in the dabigatran 110 mg group (RR, 0.84; 95% CI 0.58--1.20), and 2.07 % per year in the dabigatran 150 mg group (RR, 0.75; 95 % CI 0.52--1.08) \[[@CR34]\]. In ROCKET AF, 7468 patients (52 %) had a previous stroke or TIA. In rivaroxaban-treated patients, 2.79 events/100 PY of stroke or SEE compared with 2.96 events/100 PY occurred in warfarin-treated patients (HR, 0.94; 95 % CI 0.77--1.16) \[[@CR35]\]. Prior stroke or TIA occurred in 3436 patients (19 %) in the ARISTOTLE trial. In these patients, stroke or SEE rates were 2.5 % per year for apixaban-treated patients and 3.2 % per year for warfarin-treated patients \[[@CR23]\]. In the ENGAGE AF trial, 5973 patients (28 %) had a previous stroke or TIA. The rate of the primary efficacy outcome was 2.44 % per year with higher-dose edoxaban, 3.19 % per year with lower-dose edoxaban, and 2.85 % per year with warfarin \[[@CR25]\]. These results identify DOACs as an option in patients with AF and a history of stroke or TIA.

All of the DOACs are dependent on renal function for drug clearance, with dabigatran exhibiting the greatest renal dependence. Roughly 80 % of the absorbed dose of dabigatran is cleared by the kidneys \[[@CR11]\], 66 and 35 % of orally administered doses of rivaroxaban and edoxaban, respectively, are eliminated by kidneys \[[@CR12], [@CR13]\]. Apixaban has the least renal dependence of the DOACs, with 27 % of the oral dose cleared renally \[[@CR10]\]. Patients with renal dysfunction may experience impaired excretion of parent drugs, which can result in excessive drug accumulation and altered drug distribution and elimination \[[@CR36]\]. Due to these considerations, the US Food and Drug Administration (FDA) has issued recommendations regarding the evaluation of drugs in patients with renal impairment \[[@CR37]\], and thus, all studies included patients with moderate renal impairment (CrCl 30--50 mL/min). In RE-LY, 3505 patients (19 %) had a CrCl of \<50 mL/min. In this subset of patients, the rate of stroke or SEE was 2.15 % per year in patients treated with dabigatran 110 mg, 1.52 % per year with dabigatran 150 mg, and 2.78 % per year with warfarin \[[@CR22]\]. Patients in the ROCKET AF trial with moderate renal impairment (CrCl of 30--49 mL/min) received a reduced dose of rivaroxaban (15 mg daily). Moderate renal impairment was seen in 2950 (21 %) patients in ROCKET AF. The rate of stroke or SEE was higher in patients with moderate renal impairment than patients with CrCl \> 50 mL/min (2.32 vs. 1.57 events/100 PY in rivaroxaban-treated patients and 2.77 vs. 2.00 events/100 PY in warfarin-treated patients, respectively) \[[@CR38]\]. In the ARISTOTLE trial, 3017 patients had moderate or severe renal impairment (CrCl ≤ 50 mL/min). The rates of stroke or SEE were 2.1 % per year in apixaban-treated patients and 2.7 % per year in warfarin-treated patients \[[@CR23]\]. Major bleeding was lower in apixaban-treated patients than warfarin-treated patients (3.2 vs. 6.4 %, respectively) \[[@CR23]\]. As previously described, patients in ENGAGE AF received a 50 % decreased dose of edoxaban if they had CrCl of 30--50 mL/min, along with those who had a body weight ≤60 kg, or concomitant administration of strong P-gp inhibitors \[[@CR25]\]. Within either dosing regimen of edoxaban, the 50 % dose reduction did not impact the efficacy of edoxaban, while it did lead to a significantly greater risk reduction for major bleeding compared with those who received full dose edoxaban. For patients with a CrCl of 30--50 mL/min, the rates of stroke or SEE were similar (2.3 and 2.7 % for edoxaban 60 mg and warfarin, respectively) \[[@CR13]\]. Patients with a CrCl of 30--50 mL/min receiving higher-dose edoxaban had a lower major bleeding rate relative to warfarin (3.8 % compared with 5.1 %, respectively; HR, 0.76; 95% CI 0.58--0.99) \[[@CR13]\]. Additional post hoc analyses stratified by renal function indicated that the rates of ischemic stroke were increased with the use of edoxaban relative to warfarin in nonvalvular AF patients with CrCl \>95 mL/min due to lower plasma concentrations of edoxaban \[[@CR13], [@CR39]\]. Therefore, edoxaban should not be used in patients with AF and a CrCl \> 95 mL/min.

The efficacy and safety of DOACs is similar in patients ≥75 years of age compared with patients \<75 years of age \[[@CR40]\]. The rates of stroke or SEE are reduced relative to warfarin, and associated with a lower risk of bleeding in phase 3 trials \[[@CR22]--[@CR25]\]. Edoxaban, rivaroxaban, and apixaban exhibited no differences in efficacy or safety in elderly patients compared with younger patients \[[@CR23]--[@CR25]\]. Dabigatran has a significant interaction of age by treatment, with both 110 and 150 mg of dabigatran producing a higher risk of major bleeding in patients ≥75 compared with patients \<75 years of age \[[@CR41]\]. Edoxaban decreased the absolute risk of major bleeding, including intracranial hemorrhage, in elderly patients compared with warfarin \[[@CR42]\].

All trials included patients who had previously been on a VKA as well as VKA-naïve patients. In the RE-LY trial, 9123 patients were VKA-naïve and 8989 patients were VKA-experienced. The annualized rate of stroke and SEE in VKA-naïve patients was 1.57, 1.07, and 1.69 % for dabigatran 110 mg, dabigatran 150 mg, and warfarin, respectively (*p* = 0.65 for dabigatran 110 mg to warfarin; *p* = 0.005 for dabigatran 150 mg to warfarin) \[[@CR43]\]. In VKA-experienced patients, the primary endpoint occurred in 1.51, 1.15, and 1.74 % per year, respectively (*p* = 0.32 for dabigatran 110 mg to warfarin; *p* = 0.007 for dabigatran 150 mg to warfarin). Major bleeding rates in dabigatran-treated VKA-naïve patients were lower (dabigatran 110 mg) or similar (dabigatran 150 mg) to warfarin \[[@CR43]\]. In ROCKET AF, 6367 patients were VKA-naïve and 7897 patients were VKA-experienced. Rates of stroke and SEE were similar between rivaroxaban- or warfarin-treated patients in VKA-naïve (2.32 vs. 2.87 events/100 PY) and VKA-experienced patients (1.98 vs. 2.09 events/100 PY) \[[@CR44]\]. During the first seven days, rivaroxaban patients experienced more bleeding than warfarin patients in VKA-naïve and -experienced patients. However, after 30 days, rivaroxaban was associated with less bleeding in VKA-naïve patients and similar bleeding in VKA-experienced patients \[[@CR44]\]. In ARISTOTLE, 10,401 patients were VKA-experienced while 7800 were VKA-naïve. The primary efficacy outcome occurred in 1.1 % per year of VKA-experienced patients treated with apixaban and 1.5 % per year of VKA-experienced patients treated with warfarin \[[@CR23]\]. In VKA-naïve patients, 1.5 % per year experienced the primary outcome when treated with apixaban compared with 1.8 % per year of patients treated with warfarin. Annualized major bleeding rates were lower in patients treated with apixaban compared with warfarin in VKA-naïve (2.2 vs. 3.0 %) and VKA-experienced patients (2.1 vs. 3.2 %) \[[@CR23]\]. There were 8663 VKA-naïve and 12,441 VKA-experienced patients in ENGAGE AF. The rates of the primary efficacy endpoints were 1.49, 1.97, and 2.12 % per year with higher-dose edoxaban, lower-dose edoxaban, and warfarin, respectively, in VKA-naïve patients \[[@CR25]\]. In VKA-experienced patients the primary efficacy endpoint rates were 1.62, 2.08, and 1.60 % per year, respectively. Major bleeding rates were decreased with high- and low-dose edoxaban compared with warfarin \[[@CR25]\]. These data demonstrate that DOACs are effective in both VKA-naïve and -experienced patients.

In the RE-LY trial, 1270 patients underwent cardioversion: 647, 672, and 664 in the dabigatran 110 mg, dabigatran 150 mg, and warfarin groups, respectively. Rates of stroke and SEE were 0.8, 0.3, and 0.6 %, respectively, at 30 days \[[@CR45]\]. Rates of major bleeding were 1.7, 0.6, and 0.6 %, respectively. Cardioversion or AF ablation was completed in 321 patients in ROCKET AF \[[@CR46]\]. Rates of stroke or SEE (1.88 vs. 1.86 %) and death (1.88 vs. 3.73 %) were similar between rivaroxaban-treated and warfarin-treated patients, respectively \[[@CR46]\]. In a prospective randomized trial of rivaroxaban in patients with AF undergoing elective cardioversion, rivaroxaban was associated with a significantly shorter time to cardioversion and was associated with similar rates of major bleeding compared to VKAs \[[@CR47]\]. During ARISTOTLE, 743 cardioversions occurred in 540 patients; 265 receiving apixaban and 275 receiving warfarin. No stroke or SEE occurred during the 30-day follow-up in these patients. There was one incident of MI, one of major bleeding, and two deaths in each treatment group \[[@CR48]\]. These results represent a small number of patients, but demonstrate that DOACs are a reasonable alternative to warfarin in patients requiring cardioversion.

Determining Risk and Guideline Recommendations {#Sec14}
==============================================

Stratification schemes are available to quantify the risk of stroke in patients with AF (Table [7](#Tab7){ref-type="table"}). The CHADS~2~ score assigns 1 point each for the presence of chronic heart failure, hypertension, age ≥75 years, and diabetes mellitus; and 2 points for history of stroke or TIA \[[@CR33]\]. For each 1-point increase in the CHADS~2~ score, stroke rate increases by a factor of 1.5 (95 % CI 1.3--1.7) per 100 PY without antithrombotic therapy \[[@CR33]\]. Patients with no risk factors can be managed with aspirin or no antithrombotic therapy \[[@CR33]\]. Patients with AF who have one definitive risk factor or have two or more combination risk factors should be considered for oral anticoagulation \[[@CR49]\].Table 7Risk stratification scoring schema \[[@CR8], [@CR51]\]CHADS~2~CHA~2~DS~2-~VAScClinical CharacteristicPoints awardedClinical characteristicPoints awardedCongestive heart failure1Congestive heart failure1Hypertension1Hypertension1Age \>75 years1Age \>75 years2Diabetes mellitus1Diabetes mellitus1Prior stroke/TIA/Thromboembolism2Prior stroke/TIA/thromboembolism2Maximum score6Vascular disease (prior MI, PAD, aortic plaque)1Age 65--75 years1Sex category (female)1Maximum score9HAS-BLEDClinical characteristicPoints awardedHypertension1Abnormal renal and liver function (1 point each)1 or 2Stroke1Bleeding1Labile INRs1Elderly1Drugs or alcohol (1 point each)1 or 2Maximum score9*INR* international normalized ratio, *MI* myocardial infarction, *PAD* peripheral artery disease, *TIA* transient ischemic attack

To better identify patients with AF who are at low and moderate risk for stroke, the CHADS~2~ score has been refined to incorporate additional risk factors and is now referred to as the CHA~2~DS~2~-VASc score (Table [7](#Tab7){ref-type="table"}) \[[@CR49], [@CR50]\]. As such, the CHA~2~DS~2~-VASc is now the preferred mode for assessing stroke risk \[[@CR8], [@CR9]\].

Current guidelines for the management of AF from the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) and the European Society of Cardiology (ESC) recommend DOACs or warfarin for prevention of thromboembolism in nonvalvular AF patients with prior stroke, TIA, or CHA~2~DS~2~-VASc score ≥2, with consideration of risk of stroke, risk of bleeding, and patient preferences \[[@CR8], [@CR9]\]. No antithrombotic therapy is recommended for patients with a score of 0 \[[@CR8], [@CR9]\]. With moderate to severe chronic kidney disease, reduced doses of DOACs may be considered, although not in patients with end-stage chronic kidney disease \[[@CR8]\]. Warfarin is recommended for patients with CrCl \< 15 mL/min or on hemodialysis who have a CHA~2~DS~2~-VASc score ≥2 \[[@CR8]\]. In addition, ESC recommends that oral anticoagulation should be considered in patients with scores as low as 1, upon assessment of the risk of bleeding complications and patient preferences. The ESC recommends one of the DOACs rather than a dose-adjusted VKA for most patients when oral anticoagulation is recommended \[[@CR9]\]. The AHA/ACC/HRS recommends DOACs over warfarin only for patients who are unable to maintain a therapeutic INR \[[@CR8]\].

Stroke risk is also closely linked to bleeding risk. The use of the HAS-BLED score improves the predictive accuracy of bleeding risk and can be used in conjunction with stroke risk scores to determine if anticoagulant therapy should be initiated in patients with AF who are not undergoing antithrombotic therapy or if antiplatelet therapy is under consideration \[[@CR51]\]. A score ≥3 indicates a patient who is potentially at high risk for bleeding events \[[@CR51]\]. HAS-BLED demonstrates good predictive accuracy overall, with a better predictive accuracy for patients receiving either no antithrombotic therapy or antiplatelet therapy \[[@CR51]\]. The ESC recommends the use of the HAS-BLED bleeding risk stratification scheme in conjunction with the use of CHA~2~DS~2~-VASc \[[@CR9]\]. However, it should be noted that there is limited validation for the use of HAS-BLED. Further, bleeding risk should not be used as a reason to exclude or discontinue anticoagulation \[[@CR52]\], and patients at a high risk for stroke rarely have a bleeding risk exceeding their risk of stroke \[[@CR53], [@CR54]\].

Discussion {#Sec15}
==========

A superficial review of these trial results may convince clinicians that there are differences between the results of these agents for certain endpoints that were evaluated. While this may be a tempting conclusion, it is critical that clinicians understand that differences in the study designs and study populations make this extremely difficult.

The trials used different populations of patients in the statistical determination of noninferiority to warfarin in their primary endpoints (i.e. ITT, mITT, or per protocol). In an ITT design, the randomized subjects are analyzed in the groups to which they were assigned regardless of whether they received or adhered to their treatment. In ENGAGE-AF, the treatment period was the period between administration of the first dose of the study drug and either three days after the receipt of the last dose or the end of the double-blind therapy. Events were censored during study-drug interruptions that lasted more than three days. In the ROCKET AF study "per-protocol" "on-treatment," only subjects who fulfilled the protocol in terms of the eligibility, interventions, and outcome assessment were analyzed. This restricts the treatment comparisons to the ideal patients who adhered perfectly to the protocol stipulations. For the practicing clinician, evaluating patient adherence and the likelihood of therapy interruptions may be an important consideration in drug selection and anticipated outcomes.

Use of ITT versus on-treatment populations for noninferiority studies is controversial \[[@CR55]\] and the FDA recommends that results for noninferiority analyses be reported for both populations \[[@CR56]\]. The inclusion of all patients randomized to treatment in the ITT population avoids biases associated with switching treatment, dropout patterns, or patient selection. However, these analyses also include patient outcomes that occur after patients have ceased treatment, and include patients with poor adherence. However, exclusion of patients who have dropped out of a study, in the on-treatment population, can introduce bias toward noninferiority. Thus, when the results are robust for both populations in a study, noninferiority is firmly established \[[@CR55], [@CR56]\]. Alternately, discrepancies between the ITT and on-treatment noninferiority analyses can suggest an inclusion bias and that exclusion of patients from the on-treatment population was treatment-related \[[@CR55]\]. Only the ROCKET AF trial reported noninferiority for both on-treatment and ITT populations; *p* \< 0.001 for both (Table [5](#Tab5){ref-type="table"}).

While each of these agents has demonstrated an impressive outcome that may seem to separate it from the pack, there are also concerns that challenge this potential advantage. Dabigatran and apixaban were the only two agents to demonstrate superiority in the ITT analysis, and rivaroxaban and edoxaban did so only in the per-protocol and mITT analyses, respectively. These results may be suggestive that dabigatran and apixaban are more effective agents for the prevention of stroke and SEE in patients with nonvalvular AF. While this could be true, there are other factors that should be considered (Table [4](#Tab4){ref-type="table"}). It is important to note that in the RE-LY and ARISTOTLE trials, the mean CHADS~2~ score was only 2.2 and 2.1, respectively. By comparison, patients in the ROCKET AF and ENGAGE AF trials had a higher risk of stroke with mean CHADS~2~ score of 3.5 and 2.8, respectively. Patients with a CHADS~2~ score of 0 or 1, who may not even need anticoagulant therapy, made up about one-third of the total patients in RE-LY and ARISTOTLE, and only three patients in ROCKET AF had this level of low risk. In comparison, about one-third of patients in RE-LY and ARISTOTLE were high-risk, with a CHADS~2~ score of ≥3. The ROCKET AF trial had 87 % of patients in this high-risk group. Patients in RE-LY and ARISTOTLE consistently had lower incidence of all components of the CHADS~2~ score compared with patients in ROCKET AF and ENGAGE AF (Table [4](#Tab4){ref-type="table"}). Therefore, differences in patient populations studied are important to consider when evaluating these results.

In addition to differences in the patient populations studied, a recent reinterpretation of the DOAC phase 3 trial results suggest that the failure of rivaroxaban and higher-dose regimen edoxaban to demonstrate superiority over warfarin in their ITT analyses of the primary efficacy endpoint may be due to an imbalance of off-treatment events in the DOAC arms compared with the warfarin arms. These high discontinuation rates, coupled with more off-treatment events, would dilute the benefits of the treatment effect in the ITT analyses \[[@CR57]\].

While all of the DOACs provided a significant reduction in hemorrhagic stroke in the trials, only dabigatran provided a significant reduction in the rates of ischemic stroke compared with warfarin (Table [5](#Tab5){ref-type="table"}). In RE-LY, warfarin was administered in an open-label manner and INR was monitored and adjusted locally. In the other three trials, due to their double-blind, double-dummy designs, INR monitoring was done through standardized, encrypted, point-of-care devices that provide INR reading (real or sham) to the site investigators. This difference may result in greater variability in warfarin control at the individual patient level when warfarin is administered open-label compared with blinded, as demonstrated in an analysis of the SPORTIF (Stroke Prevention Using Thrombin Inhibitor in Atrial Fibrillation) III (open-label) and V (blinded) trials \[[@CR58]\]. While the rate of stroke and SEE was 1.2 % for ximelagatran in both studies, the efficacy outcome occurred in 2.3 % of patients receiving open-label warfarin in the SPORTIF III trial, but improved to 1.2 % with blinded warfarin in the SPORTIF V trial. Therefore, open-label warfarin resulted in a stroke and SEE rate that was almost twice that of blinded warfarin \[[@CR58]\]. Thus, it may be that in RE-LY there was greater individual INR variability that contributed to the higher ischemic stroke rate observed in the warfarin treatment group. It should also be noted that in more recent trials, such as RE-LY, warfarin management was dictated by a nomogram or algorithm \[[@CR22]\]. Therefore, fluctuations in outcomes in warfarin therapy may be less dramatic as in the older SPORTIF trials. This may explain why the TTR was lower in the ROCKET AF trial than the other DOAC trials. While investigators in the RE-LY, ARISTOTLE, and ENGAGE AF trials were provided guidance on warfarin management, investigators in the ROCKET AF trial were not and managed warfarin according to their usual practice \[[@CR22]--[@CR25]\].

The ROCKET AF patient population had the highest risk of stroke compared to the other trials, but the efficacy of rivaroxaban was not superior to warfarin based on the ITT analysis. Apixaban, with patients at lower risk for stroke (based on mean CHADS~2~ score) demonstrated superior efficacy over warfarin in its ITT analysis. However, the absolute differences in event rates in ROCKET AF and ARISTOTLE are the same. The trials also calculated the important outcome of major bleeding over different periods of time. Both apixaban and either dose of edoxaban significantly reduced major bleeding rates compared with warfarin, whereas rivaroxaban and dabigatran demonstrated similar rates of major bleeding compared with warfarin. While this may be due to truly better safety with apixaban and edoxaban, it may also be due to how bleeding events were accrued. In the ARISTOTLE and ENGAGE AF trials, bleeding events were only included if they occurred 2 or 3 days, respectively, after last dose. In the RE-LY and ROCKET AF trials, bleeding events were recorded over the duration of the study for both dabigatran and rivaroxaban.

Based on the differences discussed here, it seems difficult to suggest that one agent has a defined benefit over another in patients with nonvalvular AF. Therefore, a collective review of these data as a class of agents may be most appropriate. A meta-analysis of all 71,683 participants in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF trials compared DOACs to warfarin \[[@CR40]\]. Stroke or SEE were reduced by 19 % by DOACs compared with warfarin (RR, 0.81; 95 % CI 0.73--0.91; *p* \< 0.0001). DOACs significantly reduced all-cause mortality (RR, 0.90; 95 % CI 0.85--0.95; *p* = 0.0003) and intracranial hemorrhage (RR, 0.48; 95 % CI 0.39--0.59; *p* \< 0.0001), but increased gastrointestinal bleeding (RR, 1.25; 95 % CI 1.01--1.55; *p* = 0.04) \[[@CR40]\]. Finally, in an analysis of the net clinical benefit of the DOACs compared with warfarin based on the phase 3 clinical trials, each DOAC evaluated had a favorable net clinical benefit in comparison with warfarin \[[@CR59]\]. All four DOACs had significant net clinical benefit for the composite of disabling stroke plus life-threatening bleeding \[[@CR59]\].

As clinicians decide on the optimal DOAC for reducing the risk of stroke in a patient with AF, patient adherence should be considered. It is unlikely that patients who are nonadherent to warfarin therapy would be adherent with a DOAC, although DOACs may be advantageous in patients where nonadherence results or occurs because of frequent warfarin monitoring requirements. Another issue to consider in adherence is dosing frequency. In a study of 103 anticoagulation clinic patients, 11 patients were found to be nonadherent within 3 months of initiation of twice-daily dabigatran. Adherence was defined as taking \>80 % of required doses \[[@CR60]\]. There were also 30 % of patients who reported missing doses during this time frame, with one reporting missing a dose every day \[[@CR60]\]. An additional study of 5376 Veterans Affairs' patients evaluated adherence of twice-daily dabigatran and found a connection to outcomes. Using the same definition of adherence as the previous study, 28 % of patients were found to be nonadherent to dabigatran therapy. The investigators determined that for every 10 % decrease in adherence there was an associated 13 % increased risk of stroke and all-cause mortality \[[@CR61]\]. Therefore, once-daily DOAC therapy may be preferred to twice-daily therapy in patients in whom adherence with a more complex regimen might be a concern. While there are no comparable data to show that adherence with once-daily is better than twice-daily DOAC therapy, adherence with once-daily cardiovascular medications are typically better than twice-daily medications \[[@CR62]\]. Data on DOAC persistence are limited. Registry data suggest that rivaroxaban persistence was greater than VKA persistence, with few discontinuations due to thromboembolic complications, although bleeding was the most frequent reason for discontinuation \[[@CR63]\]. In the same registry, rates of discontinuation of dabigatran were comparable to rates for VKA, and dabigatran discontinuation was primarily due to gastrointestinal side effects \[[@CR64]\].

Limited post-marketing data are available for dabigatran. A comparison of bleeding rates for dabigatran and warfarin using insurance-claim data and administrative data from the FDA Mini-Sentinel database demonstrated similar bleeding rates for these medications from October 19, 2010 (dabigatran approval date), to December 31, 2011 \[[@CR65]\]. In patients with AF, the incidence of gastrointestinal hemorrhage in patients who received dabigatran was 1.6 per 100,000 days at risk compared with 3.5 per 100,000 days at risk in patients who received warfarin. Similarly, the intracranial hemorrhage rate was 0.8 per 100,000 days at risk in patients who received dabigatran and 2.4 per 100,000 days at risk in patients who received warfarin \[[@CR65]\]. To date, the dabigatran post-marketing data mirror trial results \[[@CR66]\].

Post-marketing data are also available for rivaroxaban from the Department of Defense electronic medical record \[[@CR67]\]. Data were collected from January 1, 2013, to March 31, 2014, in 27,467 patients with nonvalvular AF to evaluate major bleeding. The incidence of major bleeding in these patients was 2.9 per 100 PY, which is similar to the 3.6 per 100 PY demonstrated in the ROCKET AF trial. Use of rivaroxaban in a "real world" setting does not seem to be associated with an increased risk of major bleeding.

In a recent literature review, 26 published cases of severe hemorrhagic complications with dabigatran and two such cases for rivaroxaban were presented \[[@CR68]\]. Cases were assessed for three risk factors of hemorrhagic complications: (1) prescriber error; (2) renal impairment; or (3) age \>80 years with body weight \<60 kg. At least one of these three risk factors was present in 78 % of cases \[[@CR68]\]. This suggests that clinicians must make informed choices in determining the appropriate DOAC for each patient. In summary, the introduction of DOACs, while simplifying treatment, may generate additional controversy because DOAC trials were different enough from each other that direct comparison among them is not possible.

Conclusion {#Sec16}
==========

The DOACs provide further options for patients with nonvalvular AF at risk for stroke in addition to traditional therapy with warfarin. The clinician has several individual patient factors to consider including risk factors, tolerability, patient preference, potential for drug interaction, and other clinical characteristics. The DOACs have demonstrated efficacy and safety that are similar to or better than warfarin in large, randomized clinical trials and are valuable alternatives to warfarin in patients with nonvalvular AF.
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